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Radiation therapyAbstract Primary thyroid lymphoma (PTL) is deﬁned as a lymphoma involving only the thyroid
gland or both thyroid gland and neck lymph nodes, without contiguous spread or distant metas-
tases from other areas of involvement at diagnosis. Despite its rarity, PTL should be promptly
recognized because its management is quite different from the treatment of other neoplasms of
the thyroid gland.
In the present study, we report a case of PTL treated by surgery and adjuvant chemotherapy.
Otherwise, literature review allowed us to deﬁne main characteristics of this located lymphoma.
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A 67-year-old woman presented with a rapidly growing
(2 weeks) painless thyroid enlargement with a left supra-
clavicular neck mass, without compressive symptoms. The
CT scan showed a multi nodular goiter with a suspicious leftnodule measuring 3 cm. It also showed lymph nodes of left
II, III, IV groups, two of which were necrotic, without other
abnormalities (Fig. 1).
Fine Needle Aspiration of both thyroid nodule and supra
clavicular lymphadenopathy found suspicious cells suggestive
of malignancy.
She had, then, undergone total thyroidectomy with radical
left neck dissection taking away the jugular vein and sterno-
cleido-mastoid muscle. Frozen section exam revealed meta-
static lymphadenopathy and unspeciﬁed thyroid malignant
neoplasm. Postoperative course was marked by acute dyspnea,ed.
Figure 1 Axial section injected CT: multi nodular goiter with a
suspicious left nodule measuring 3 cm ; adenopathies of left II,
III, IV groups .
172 F. Hedhili et al.related to left vocal cord paralysis, which needed a
tracheotomy.
Deﬁnitive histology (Fig. 2) concluded to diffuse large
B-cell Lymphoma of thyroid with metastatic regional lymph
nodes.
Assigned Ann Arbor classiﬁcation was IIE. Treatment was,
hence, completed by chemotherapy. She had six RCHOP
chemotherapy cycles (Rituximab–Cyclophosphamide–doxoru
bicine–vincristine–prednisone). After 12 months follow-up,
our patient is disease free.
2. Discussion
Primary thyroid lymphoma is an uncommon pathological
entity and constitutes 5% of all thyroid malignancies. It occurs
in less than 3% of all non-Hodgkin’s extra-nodal lymphomas.1
It is an uncommon condition which, to be categorized as such,
must only affect the thyroid gland and, eventually, the loco-
regional lymph nodes. Primary disease in other location should
be ruled out. Diagnosis of PTL is complex, and surgery is often
required to make a deﬁnitive diagnosis. Therapeutic manage-
ment has greatly changed over time, and chemotherapy, with
or with-out radiotherapy is the current treatment of choice.
PTL is more commonly observed in females than in males
(F/M= 4/1). Most patients present in the 7th decade of life
(average age e 67 years), with a rapidly enlarging neck mass.1,2
Preexisting chronic autoimmune (Hashimoto’s) thyroiditis is aFigure 2 Pathologic aspect in hematoxylin eosin stainwell-recognized risk factor predisposing to the development of
PTL.3 It has been reported that the risk of PTL among patients
with autoimmune (Hashimoto’s) thyroiditis is 40 times greater
compared to that of the general population. It takes a long
time (20–30 years) to develop PTL after the onset of lympho-
cytic thyroiditis.3
Normally, the thyroid gland does not contain native
lymphoid tissue. Intra-thyroid lymphoid tissue develops
under pathological conditions, and mainly in patients with
autoimmune (Hashimoto’s) thyroiditis, probably as a result
of chronic antigenic stimulation. This acquired lymphoid
tissue resembles mucosa-associated lymphoid tissue and
can evolve to non-Hodgkin lymphoma of B-cell origin,
which is the most common type of PTL. Diffuse large B-
cell lymphoma (DLBCL) and extra-nodal marginal zone
B-cell lymphoma of mucosa-associated lymphoid tissue
(MALT) lymphoma are its common subtypes (representing
70% and 15–30% of all primary non-Hodgkin PTLs,
respectively.4–6
A rapidly growing (usually within 1–3 months), painless
thyroid enlargement, either in the form of goiter or discrete
nodule, is the most common clinical presentation in PTL.
Pressure symptoms (dysphagia, dyspnea, stridor, cough,
hoarseness, superior vena cava syndrome) are often present.
This clinical presentation can be confused with anaplastic thy-
roid carcinoma like in our case. Because of the frequent coex-
istence of Hashimoto’s thyroiditis, many patients are
hypothyroid or under thyroid hormone replacement therapy.4
Classic B-type symptoms of fever, night sweats and weight loss
are less common. Clinical examination can detect diffuse or
nodular thyroid enlargement.
Because of the frequent coexistence of Hashimoto’s thy-
roiditis, circulating antibodies to thyroid peroxidase are posi-
tive in a large percentage of patients (60%).7
Imaging studies (ultrasonography, computed tomography)
reveal a diffusely enlarged thyroid gland (resembling goiter)
or a nodular thyroid gland (solitary or multiple thyroid nod-
ules, commonly cold), mimicking thyroiditis or a primary thy-
roid follicular lesion.
Nowadays, ﬁne-needle aspiration (FNA) is an essential tool
in the management of thyroid diseases. However, FNA has
yielded inconsistent results in the diagnosis of PTL. Rates of
achieving a positive diagnosis range widely, in the literature,
from 25% up to 90%.7,8 PTL should be strongly considered
when the aspirated specimen predominantly consists of
lymphocytes.
PTL should be differentiated from lymphomas at other
sites. This is especially important given the rarity of PTL. In
this case, lymphoma of the thyroid gland could be the resultand immuno-histo-chemistry (CD 20 and KI 67).
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Moreover, PTL should be differentiated from Hashimoto’s
thyroiditis and from poorly differentiated, undifferentiated
or anaplastic thyroid carcinomas. Adjunctive techniques
(immuno-histo-chemistry, ﬂow cytometry, etc.) are of particu-
lar importance in differentiating PTL from anaplastic thyroid
carcinoma; this is an important consideration given that man-
agement and prognosis of these two diseases is totally
different.
The role of surgery in the management of PTL remains
highly controversial. There are reports in the literature sup-
porting the role of surgery in the management of selected
patients with PTL. Surgery alone has been proposed for the
management of localized (stage IE, ANN ARBOR
Classiﬁcation) intra-thyroidal lymphoma.9–12 When there is
any question of incomplete surgical resection, adjuvant exter-
nal beam radiation therapy should be considered
postoperatively.
Like surgery, external beam radiation therapy alone has
been proposed for the management of localized (stage IE) lym-
phoma. There is evidence that radiation therapy can achieve
local control of the disease. The radiation ﬁeld includes the
neck plus the upper mediastinum and the treatment dose is
moderate (30–50 Gy).13
Chemotherapy can control distant dissemination of the dis-
ease, while radiation therapy can achieve local control of the
lymphoma. The conventional chemotherapeutic regimen for
PTL includes cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP). Typically, patients with PTL respond
rapidly to this regimen. Systemic chemotherapy is usually asso-
ciated with the typical radiation therapy (chemo-radiation
therapy). Most commonly, radiation therapy is used after
3–6 courses of chemotherapy.10,12 Combined chemo-radiation
therapy is associated with a signiﬁcantly lower risk of distant
failure. Rituximab has recently been effectively used (with
cyclophosphamide, mitoxantrone, vincristine, and pred-
nisolone) in elderly patients with diffuse large B-cell lymphoma
of thyroid.14
The prognosis of patients depends on the histological
grade of the tumor and the stage of the disease. MALT lym-
phomas tend to have a more indolent course and a better
prognosis compared with patients with diffuse large B-cell
lymphoma (DLBCL) or mixed histological subtypes, which
have a more aggressive clinical course. Patients with MALT
lymphoma had signiﬁcantly higher complete response rates
than those with DLBCL both for early as well as for
advanced disease. Overall, 5-year survival ranges between
50 and 60%.2,15,16References
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